TD Cowen initiated coverage of Tonix Pharmaceuticals (TNXP) with a Buy rating and $22 price target The firm cites Tonmya’s potential in fibromyalgia for the Buy rating. Consultants indicate Tonmya’s early real-world efficacy is positive for pain and sleep, in a “large and underserved market,” where 5% target penetration reflects $600M in sales, the analyst tells investors in a research note. In addition, TD believes Tonix’s pipeline success with TNX-4800 “adds an intriguing opportunity” in Lyme disease prophylaxis.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharma Announces Administrative Update to Regulatory Filing
- Tonix Pharmaceuticals says on track to initiate Phase 2 study of TNX-4800
- Tonix Pharma Advances TNX-4800 Lyme Disease Prevention Program
- Tonix Pharma Highlights Preclinical Progress in Oncology Pipeline
- Tonix Pharmaceuticals publishes Tonmya study data findings